Developer docs
API playgroundTry for free, no card

Search company profiles

Evelo Biosciences

Full company profile

uuid0004nxn

Namestring
Evelo Biosciences
Legal namestring
Evelo Biosciences, Inc.
Websiteurl
evelobio.com
Company typeenum
Public
Founded yearint
2015
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
immunomodulatory therapeutics, oral biologics, inflammatory disease treatment, gut-immune axis, clinical-stage biopharmaceuticals
Industry1 code
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Immunomodulatory Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical development and commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company. Revenue expected upon regulatory approval and commercialization of therapeutic candidates EDP1815 and EDP2939 for inflammatory diseases.

defenseworld.net
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Evelo Biosciences is a clinical-stage biotechnology company that develops oral biologic therapeutics derived from gut commensal bacteria to modulate immune responses through the small intestinal axis. Its lead candidates, EDP1815 and EDP2939, are designed to treat inflammatory diseases, with Phase 2a clinical trials in psoriasis underway.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 2a clinical trial in psoriasis underway
Product overview1 text field

Evelo Biosciences is a clinical-stage biotechnology company developing immunomodulatory therapies targeting gut-immune interactions for the treatment of various diseases. The company is advancing two lead drug candidates, EDP1815 and EDP2939, both focused on inflammatory disease treatments. Evelo Biosciences is currently conducting Phase 2a clinical trials for psoriasis using its lead therapeutic candidates.

Product and service1 record
1EDP1815
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeBroad incumbent
Description

Major biopharmaceutical company with an established immunology and inflammation portfolio including Otezla and Enbrel. Operates broadly in the same inflammatory disease space as Evelo's lead candidates.

TypeBroad incumbent
Description

Global biopharmaceutical company with growing immunology presence (e.g., Taltz, Olumiant) and active in inflammatory disease R&D. Comparable large-pharma incumbent competing in Evelo's target indications.

TypeDirect peer
Description

Pioneer in microbiome-based therapeutics with lead programs in inflammatory disease and recurrent C. difficile. Comparable to Evelo as a clinical-stage developer of microbial consortia designed to modulate gut-immune pathways for systemic therapeutic effect.

TypeEmerging player
Description

Clinical-stage developer of oral microbial therapies, including programs in inflammatory bowel disease and recurrent C. difficile. Comparable microbial modality and inflammatory disease pipeline overlap with Evelo.

TypeDirect peer
Description

Clinical-stage biotech developing defined bacterial consortia that modulate the gut-immune axis to treat inflammatory and autoimmune diseases. Closely comparable to Evelo's commensal bacteria-derived oral biologic platform and target indications.

64D Pharma
TypeDirect peer
Description

UK-based clinical-stage biotech developing live biotherapeutic products for cancer and gastrointestinal disease. Directly comparable to Evelo's oral microbial therapeutic modality and gut-immune targeting approach.

TypeBroad incumbent
Description

Global biopharmaceutical leader with a dominant immunology franchise including Skyrizi, Risankizumab, and Humira for psoriasis and inflammatory diseases. Represents the established standard of care that Evelo's oral gut-immune approach must differentiate against.

8Bristol-Myers Squibb
TypeBroad incumbent
Description

Major immunology player with approved biologics for psoriasis and inflammatory diseases (e.g., Sotyktu, Zeposia). Competes in Evelo's target inflammatory disease space and is a likely partner or acquirer of differentiated novel mechanisms.

9Second Genome
TypeEmerging player
Description

Clinical-stage biotech using microbiome science to develop therapeutics for inflammatory bowel disease and other inflammatory conditions. Shares Evelo's gut-microbiome-derived therapeutic strategy and inflammatory disease focus.

TypeBroad incumbent
Description

Diversified biopharmaceutical company with a major immunology franchise including Tremfya and Stelara for psoriasis and IBD. Comparable large-pharma presence in Evelo's target indications and a potential strategic partner for novel oral mechanisms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Evelo Biosciences

Immunomodulatory Biopharmaceuticalsevelobio.com

Evelo Biosciences firmographics

Firmographics
Name
Evelo Biosciences
Legal name
Evelo Biosciences, Inc.
Website
https://evelobio.com
Company type
Public
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Evelo Biosciences industry classification

Industry
Product category
Immunomodulatory Biopharmaceuticals
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Immunomodulatory therapeutics
  • Oral biologics
  • Inflammatory disease treatment
  • Gut-immune axis
  • Clinical-stage biopharmaceuticals

Where Evelo Biosciences is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Evelo Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Pharmaceutical development and commercialization: Pre-revenue clinical-stage biotech company. Revenue expected upon regulatory approval and commercialization of therapeutic candidates EDP1815 and EDP2939 for inflammatory diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Evelo Biosciences product offering

Product offering

Core offering

Evelo Biosciences is a clinical-stage biotechnology company that develops oral biologic therapeutics derived from gut commensal bacteria to modulate immune responses through the small intestinal axis. Its lead candidates, EDP1815 and EDP2939, are designed to treat inflammatory diseases, with Phase 2a clinical trials in psoriasis underway.

Product overview

Evelo Biosciences is a clinical-stage biotechnology company developing immunomodulatory therapies targeting gut-immune interactions for the treatment of various diseases. The company is advancing two lead drug candidates, EDP1815 and EDP2939, both focused on inflammatory disease treatments. Evelo Biosciences is currently conducting Phase 2a clinical trials for psoriasis using its lead therapeutic candidates.

Differentiator

Problem solved

Functional benefit

Products and services

  • EDP1815

Quantifiable outcome

  • Phase 2a clinical trial in psoriasis underway

Companies that use Evelo Biosciences

Customer profile

Segments1 record

Ideal customer profiles2 records

Evelo Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Evelo Biosciences partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Evelo Biosciences competitors and assessment

Company assessment

Broad incumbents

  • Amgen: Major biopharmaceutical company with an established immunology and inflammation portfolio including Otezla and Enbrel. Operates broadly in the same inflammatory disease space as Evelo's lead candidates.
  • Eli Lilly: Global biopharmaceutical company with growing immunology presence (e.g., Taltz, Olumiant) and active in inflammatory disease R&D. Comparable large-pharma incumbent competing in Evelo's target indications.
  • AbbVie: Global biopharmaceutical leader with a dominant immunology franchise including Skyrizi, Risankizumab, and Humira for psoriasis and inflammatory diseases. Represents the established standard of care that Evelo's oral gut-immune approach must differentiate against.
  • Bristol-Myers Squibb: Major immunology player with approved biologics for psoriasis and inflammatory diseases (e.g., Sotyktu, Zeposia). Competes in Evelo's target inflammatory disease space and is a likely partner or acquirer of differentiated novel mechanisms.
  • Johnson & Johnson: Diversified biopharmaceutical company with a major immunology franchise including Tremfya and Stelara for psoriasis and IBD. Comparable large-pharma presence in Evelo's target indications and a potential strategic partner for novel oral mechanisms.

Direct peers

  • Seres Therapeutics: Pioneer in microbiome-based therapeutics with lead programs in inflammatory disease and recurrent C. difficile. Comparable to Evelo as a clinical-stage developer of microbial consortia designed to modulate gut-immune pathways for systemic therapeutic effect.
  • Vedanta Biosciences: Clinical-stage biotech developing defined bacterial consortia that modulate the gut-immune axis to treat inflammatory and autoimmune diseases. Closely comparable to Evelo's commensal bacteria-derived oral biologic platform and target indications.
  • 4D Pharma: UK-based clinical-stage biotech developing live biotherapeutic products for cancer and gastrointestinal disease. Directly comparable to Evelo's oral microbial therapeutic modality and gut-immune targeting approach.

Emerging players

  • Finch Therapeutics: Clinical-stage developer of oral microbial therapies, including programs in inflammatory bowel disease and recurrent C. difficile. Comparable microbial modality and inflammatory disease pipeline overlap with Evelo.
  • Second Genome: Clinical-stage biotech using microbiome science to develop therapeutics for inflammatory bowel disease and other inflammatory conditions. Shares Evelo's gut-microbiome-derived therapeutic strategy and inflammatory disease focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Evelo Biosciences social profiles

Digital presence

Evelo Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Evelo Biosciences leadership team

Management profile

Number of profiles

Profiles9 records

Evelo Biosciences funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Evelo Biosciences M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Evelo Biosciences

What does Evelo Biosciences do?

Evelo Biosciences is a clinical-stage biotechnology company that develops oral biologic therapeutics derived from gut commensal bacteria to modulate immune responses through the small intestinal axis. Its lead candidates, EDP1815 and EDP2939, are designed to treat inflammatory diseases, with Phase 2a clinical trials in psoriasis underway.

Is Evelo Biosciences a public or private company?

Evelo Biosciences is a public company. It is classified as public and is currently operating.

When was Evelo Biosciences founded?

Evelo Biosciences was founded in 2015. It employs 11 to 50 people.

Where is Evelo Biosciences based?

Evelo Biosciences is headquartered in Cambridge, United States, in the North America region.

How does Evelo Biosciences make money?

One revenue line is on record: pharmaceutical development and commercialization.

Who are Evelo Biosciences's main competitors?

Broad incumbents on record are Amgen, Eli Lilly, AbbVie, Bristol-Myers Squibb and Johnson & Johnson. Direct peers are Seres Therapeutics, Vedanta Biosciences and 4D Pharma. Emerging players are Finch Therapeutics and Second Genome.

Does Evelo Biosciences have an API?

No public API is recorded for Evelo Biosciences.

What industry is Evelo Biosciences in?

Evelo Biosciences's product category is Immunomodulatory Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterEvelo Biosciences calls it a dayEvelo Biosciences announced its intention to dissolve the company in accordance with Delaware General Corporation Law, a move approved by the board in the best interests of stockholders. The announcement triggered a 10.5% increase in the firm's shares to $0.65 during trading.American City Business JournalsEvelo, Singer, Sullivan & Bruegge assets hit $11.4BThe article reports that Evelo, Singer, Sullivan & Bruegge assets have reached $11.4 billion, highlighting recent growth in the investment sector. The Cincinnati Business Courier notes the expansion of a major investment team and related industry activity.Stock TitanAcadia Pharma adds finance veteran Poole to boardAcadia Pharmaceuticals appointed Jonathan M. Poole to its Board of Directors on March 3, 2026, as part of its strategic growth initiatives. Mr. Poole's experience includes leadership roles at Vertex Pharmaceuticals, Evelo Biosciences, and Genocea Biosciences, focusing on finance and global expansion. The company is developing therapies for neurological and rare diseases with an expanding pipeline.BenzingaBest Biotech Penny Stocks Right Now • Updated Daily • BenzingaBenzinga profiles several biotech penny stocks, including Precigen, Sonnet BioTherapeutics, Vaccinex, Vivos Therapeutics, and Evelo Biosciences, detailing their product pipelines and clinical-stage candidates. The article notes investor interest in biotech due to COVID-19 vaccine hype, while warning of penny stock volatility and the need for careful research.MedCity NewsEvelo Bio Shutdown Follows a Series of Microbiome Therapy Trial FailuresEvelo Biosciences announced plans to dissolve the company following a series of clinical trial failures for its microbiome therapies and an inability to secure additional financing. The board determined that dissolution offers the best opportunity for recovering value for creditors and stakeholders after key drug candidates failed to meet primary endpoints in Phase 2 trials.BioPharma DiveFlagship-backed microbiome biotech Evelo to shut downEvelo Biosciences is shutting down following setbacks, including the failure of its lead drug candidate for inflammatory skin conditions in a Phase 2 trial. The company, launched by Flagship Pioneering, has struggled to find alternative funding sources and has already laid off employees, with its shares losing almost all value since its 2018 debut. Despite Evelo's closure, the biopharma sector as a whole continues to grow in employment for mid-sized and large companies.FierceBiotechEvelo's voyage ends as Flagship-founded biotech finds dissolution is only viable optionEvelo Biosciences has filed for dissolution after failing to secure funding or strategic alternatives, with its board and executives stepping down as the company prepares to pay creditors. The biotech's decision follows the failure of all three clinical drug candidates in trials for conditions such as atopic dermatitis and psoriasis. Insolvency expert Craig Jalbert will oversee the process while Rock Creek Advisors assists in monetizing remaining assets.STATEvelo Biosciences, a microbiome company launched by Flagship, shuts downEvelo Biosciences, a microbiome biotech startup launched in 2015, is shutting down due to cash shortages and multiple drug trial failures. The company focused on treating various cancers by leveraging the human microbiome but failed to bring products to market despite the sector seeing recent regulatory approvals for other entities.BenzingaTop 4 Health Care Stocks That May Rocket Higher This Month - EVELO BIOSCIENCES INC by Evelo Biosciences,This article uses RSI (Relative Strength Index) analysis to identify four oversold healthcare stocks as potential buying opportunities. The companies featured are Spruce Biosciences (which completed enrollment for a CAHmelia-203 clinical study in adult classic congenital adrenal hyperplasia), Generation Bio (downgraded by TD Cowen from Outperform to Market Perform), LumiraDx (which posted downbeat Q2 results and submitted its first 510(k) application to the FDA for a COVID Ultra test), and Evelo Biosciences (which failed to achieve the primary endpoint in its Phase 2 clinical study with EDP2939 in moderate psoriasis and initiated a process to explore strategic alternatives).GlobeNewswireEvelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate PsoriasisEvelo Biosciences announced top-line results from its Phase 2 study with EDP2939 in moderate psoriasis, where the primary endpoint was not achieved. The company will cease development of EDP2939 and is exploring strategic alternatives, including partnering on EDP1815 and its SINTAX platform.